Mealey's (June 28, 2018, 4:01 PM EDT) -- WASHINGTON, D.C. — A Delaware federal judge’s finding of nonobviousness, following a bench trial, with regard to a patented formulation of zolmitriptan nasal spray suitable for intranasal administration was affirmed June 28 by the Federal Circuit U.S. Court of Appeals (Lannett Holdings Inc., et al. v. Impax Laboratories Inc., et al., No. 17-2020, Fed. Cir.)....